DataLabs Announces Industry's First Middleware Product Built Specifically for the Biopharmaceutical Industry
New integration platform leverages a library of predefined connectors and allows clients to write their own custom connectors, easing the pain of creating and managing system integrations.
IRVINE, Calif.-June 14, 2006-DataLabs, an innovative developer of Internet-based software applications for clinical development, today announced the release of DataLabs Connect™ v2.0. DataLabs Connect is an enterprise-level middleware product built specifically for the biopharmaceutical industry. A first for the industry, DataLabs Connect includes an application server, management portal, connector framework and predefined connectors that integrate the entire suite of DataLabs' products including Galt Associates dsNavigator encoding and dictionary management product and other best-of-breed products.
DataLabs will be at booth #1829 at the DIA Annual Conference
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
January 30th 2025The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial hypertension, making it unethical to continue.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
